• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Format

    3/28/24 6:05:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email

    The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, multifunctional benefits and a 40-year legacy of farm-direct transparency and traceability.

    Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving.

    At the forefront of natural microalgae innovation, Nutrex-Hawaii addresses the evolving preferences of today's discerning consumers with its new gummies, offering a host of distinct benefits:

    • Sourced from natural Hawaiian microalgae grown outdoors under natural sun – never synthetic, fermented, nor cultivated in laboratory environments, as much of today's astaxanthin is sourced,
    • Backed by scientific research supporting comprehensive, full body health objectives of today's consumer,
    • Grown in Hawaii, ensuring unparalleled origin traceability and sustainability.

    "Today's consumers seek brands that align with their values of efficacy, transparency, and sustainability. With our demonstrated 40-year legacy of Hawaiian microalgae production and innovation, we're enthusiastic about providing a safe, responsible, and sustainable solution that caters to the growing global interest in gummies with multi-functional benefits," stated Collette Kakuk, Chief Strategic and Commercial Officer. "Our new BioAstin® Hawaiian Astaxanthin® gummies offer consumers a convenient way to experience the benefits of our number 1 selling brand, in an easy to consume and tasty gummy format."

    BioAstin®, derived from natural Hawaiian Astaxanthin®, is a powerful natural antioxidant extracted from Haematococcus pluvialis algae, renowned for its tangible health benefits for diverse health goals, including not only healthy agers, but also active lifestyle and beauty from within audiences. The benefits of BioAstin® Hawaiian Astaxanthin® are supported by longstanding, robust clinical science, encompassing eye, skin, joint, and heart health, as well as healthy inflammatory response and post-exercise recovery☨.

    "With antioxidant potency 6000 times greater than Vitamin C, our BioAstin® Hawaiian Astaxanthin® gummies provide consumers with powerful benefits for full body wellness. Our 12mg formulation sets our gummies apart from others in the market, including exciting skin health claims important to consumers today, such as improving moisture retention and hydration☨, reducing appearance of wrinkles☨, and also skin health during UV and sun exposure☨," added Kakuk.

    The gummies are further enhanced with 25mcg (1000 IU) of vitamin D3, and are sugar free, sweetened with monk fruit and stevia, non-GMO, gluten-free, and vegan.

    The new gummies were soft launched at the recent Natural Products Expo West and are currently being nationally rolled out in mass and specialty retail channels and are also available on Amazon.com and https://www.nutrex-hawaii.com.

    For more information about Nutrex-Hawaii and BioAstin® Hawaiian Astaxanthin® gummies, please visit https://www.nutrex-hawaii.com.

    About Nutrex-Hawaii, Inc.: Nutrex-Hawaii, a wholly owned subsidiary of Cyanotech Corporation, is the global leader in natural, premium microalgae dietary supplements for health and wellness, leading the natural channel category with its BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® brands. All Nutrex-Hawaii microalgae products are naturally and sustainably produced on a purpose-built 96-acre facility in Kona, Hawaii. Distributed through premium retail locations in the United States, including Whole Foods, Sprouts, Costco, and online at Amazon.com and https://www.nutrex-hawaii.com, Nutrex-Hawaii products are trusted by consumers worldwide.

    ☨These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnosis, treat, cure or prevent any disease.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240328602781/en/

    Get the next $CYAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/3/24 3:27:06 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/1/24 4:42:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/27/24 1:33:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    SEC Filings

    See more
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      5/8/25 3:56:11 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      2/11/25 4:01:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      12/16/24 1:53:10 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by VP of Sales Brand Jennifer Kimberly

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:06:36 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, HR, Secretary Nordin Amy Beth

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:04:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, Operations Jensen Glenn

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:02:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      10/3/24 6:39:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/12/24 12:25:52 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/6/24 12:45:58 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Financials

    Live finance-specific insights

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care